[
    [
        {
            "time": "",
            "original_text": "康业元再发声：公司要求从未止于分红！",
            "features": {
                "keywords": [
                    "康业元",
                    "分红",
                    "要求"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康业元再发声：公司要求从未止于分红！",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康业元回应白云山澄清公告：“金戈”收入、利润大增后，广药开始毁约",
            "features": {
                "keywords": [
                    "康业元",
                    "白云山",
                    "金戈",
                    "收入",
                    "利润",
                    "毁约"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康业元回应白云山澄清公告：“金戈”收入、利润大增后，广药开始毁约",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "国产伟哥之争继续 康业元再发公开信称将一一回应广药",
            "features": {
                "keywords": [
                    "国产伟哥",
                    "康业元",
                    "广药",
                    "公开信"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "国产伟哥之争继续 康业元再发公开信称将一一回应广药",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "李楚源遭康业元千字“逼问”：为何不敢出来一一答复",
            "features": {
                "keywords": [
                    "李楚源",
                    "康业元",
                    "逼问",
                    "答复"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "李楚源遭康业元千字“逼问”：为何不敢出来一一答复",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "广药集团“举报门”持续发酵：康业元今日再发举报信 直指广药董事长李楚源“违法违纪” 诉讼纠纷",
            "features": {
                "keywords": [
                    "广药集团",
                    "举报门",
                    "康业元",
                    "李楚源",
                    "违法违纪",
                    "诉讼纠纷"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "广药集团“举报门”持续发酵：康业元今日再发举报信 直指广药董事长李楚源“违法违纪” 诉讼纠纷",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "利益分配不均 金戈小股东“挨欺负”状告白云山 诉讼纠纷",
            "features": {
                "keywords": [
                    "利益分配",
                    "金戈",
                    "小股东",
                    "白云山",
                    "诉讼纠纷"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "利益分配不均 金戈小股东“挨欺负”状告白云山 诉讼纠纷",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "金戈归谁？白云山、康业元利益分配纠纷升级 诉讼纠纷",
            "features": {
                "keywords": [
                    "金戈",
                    "白云山",
                    "康业元",
                    "利益分配",
                    "纠纷升级",
                    "诉讼纠纷"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "金戈归谁？白云山、康业元利益分配纠纷升级 诉讼纠纷",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "首个国产伟哥药金戈连续5年毛利率超80% 康业元白云山利益分配纠纷升级 诉讼纠纷",
            "features": {
                "keywords": [
                    "国产伟哥",
                    "金戈",
                    "毛利率",
                    "康业元",
                    "白云山",
                    "利益分配",
                    "纠纷升级",
                    "诉讼纠纷"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "首个国产伟哥药金戈连续5年毛利率超80% 康业元白云山利益分配纠纷升级 诉讼纠纷",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]